Matthew L Rizk Selected Research

Tazobactam

4/2021	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
11/2020	In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa.
1/2020	Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
3/2019	Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
1/2019	Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew L Rizk Research Topics

Disease

17	Infections 01/2022 - 10/2012
4	Body Weight (Weight, Body) 01/2022 - 01/2016
4	Intraabdominal Infections 01/2020 - 10/2016
4	Urinary Tract Infections (Urinary Tract Infection) 01/2020 - 11/2018
3	Bacterial Pneumonia 01/2022 - 01/2018
3	Gram-Negative Bacterial Infections 01/2019 - 10/2016
2	Critical Illness (Critically Ill) 12/2021 - 04/2021
2	Bacterial Infections (Bacterial Infection) 04/2021 - 10/2019
1	AIDS-Related Complex (ARC) 04/2021
1	COVID-19 12/2020
1	Malaria 12/2020
1	Pneumonia (Pneumonitis) 11/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Ventilator-Associated Pneumonia 01/2020
1	Renal Insufficiency (Renal Failure) 01/2019
1	Immune Reconstitution Inflammatory Syndrome 12/2015
1	Exanthema (Rash) 12/2015
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2014
1	Breast Neoplasms (Breast Cancer) 01/2014
1	HIV Infections (HIV Infection) 01/2014
1	Obesity 04/2010
1	Insulin Resistance 04/2010

Drug/Important Bio-Agent (IBA)

8	relebactamIBA 01/2022 - 10/2016
7	Imipenem FDA Link 01/2022 - 01/2016
6	tazobactam drug combination ceftolozaneIBA 04/2021 - 11/2018
5	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 01/2022 - 10/2016
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 04/2016
5	ceftolozaneIBA 04/2021 - 01/2019
5	Tazobactam FDA LinkGeneric 04/2021 - 01/2019
4	CreatinineIBA 01/2022 - 01/2016
4	Raltegravir Potassium FDA Link 01/2018 - 01/2014
3	Pharmaceutical PreparationsIBA 11/2018 - 12/2015
3	IntegrasesIBA 01/2018 - 11/2016
2	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 01/2022 - 12/2021
2	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2020 - 01/2019
1	tedizolid phosphateIBA 11/2021
1	tedizolidIBA 11/2021
1	Oxazolidinones (2 Oxazolidone)IBA 11/2021
1	quinolineIBA 12/2020
1	Azithromycin (Zithromax)FDA LinkGeneric 12/2020
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 12/2020
1	Chloroquine (Aralen)FDA LinkGeneric 12/2020
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2018
1	acivicin (AT 125)IBA 01/2018
1	LactamsIBA 01/2018
1	Reverse Transcriptase InhibitorsIBA 01/2017
1	NucleosidesIBA 01/2017
1	doravirineIBA 01/2017
1	dolutegravirIBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2014
1	Integrase InhibitorsIBA 01/2014
1	Human immunodeficiency virus 1 p31 integrase proteinIBA 10/2012
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2010
1	Nonesterified Fatty Acids (NEFA)IBA 04/2010
1	Glucose (Dextrose)FDA LinkGeneric 04/2010
1	LipidsIBA 04/2010
1	glyoxylic acid (glyoxylate)IBA 04/2010

Therapy/Procedure

2	Mechanical Ventilators (Ventilator) 01/2022 - 12/2021
2	Therapeutics 01/2017 - 11/2014
1	Intravenous Infusions 01/2019